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Protein kinase C purified from rat brain was found to be inhibited by suramin, a substance used originally in the therapy of antitrypanosomic 
infections and more recently proposed as antineoplastic agent. The inhibition of suramin was competitive with one of the substrates of the enzyme, 
ATP with a K, of 10 PM. At concentrations adequate to inhibit the isolated enzyme, suramin was shown to slow the rate of proliferation of neuro- 
blastoma NB2A cells in vitro and to induce their differentiation as evidenced by typical morphological changes. 
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1. INTRODUCTION 
Suramin, a polysulphonated naphthylurea, was the 
first widely accepted antiparasitic drug to be developed 
and is still one of the most commonly prescribed an- 
titrypanosomal drugs. The inhibition of protein kinases 
in Trypanosomatida by suramin has been demonstrated 
[ 1,2]. In recent studies suramin was used in the chemo- 
therapy of acquired immune deficiency syndrome 
(AIDS) [3] but host toxicity precluded its usefulness. 
The drug is currently under investigation for the treat- 
ment of advanced malignancy and has exhibited an- 
titumor activity in a number of systems [4]. Protein 
kinase C’, a Ca’+- and phospholipid-dependent protein 
kinase has been implicated in numerous biological pro- 
cesses including tumor promotion and differentiation 
(for review see [5,6]). Since suramin has been shown to 
interact with other kinases we have considered and 
tested the possibility that suramin antitumor activity is 
due to its inhibition of protein kinase C. 
2. MATERIALS AND METHODS 
2.1. Materials 
Suramin, a generous gift from the World Health Organization 
(Geneva, Switzerland), was prepared as a stock solution of 10 mg/ml 
in distilled water and stored at -20°C. Human erythrocytes were ob- 
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tained from the Swiss Red Cross and calf thymus histone III-S was 
isolated by the procedure of De Nooij and Westenbrink [7]. Leupep- 
tin was from Fluka (Buchs, Switzerland) and phosphatidylserine 
from Lipid Products (S. Nutfield, Surrey, England). Cell culture 
medium and serum were from Gibco (Grand Island, NY). 
[Y-~~P]ATP was supplied by Amersham (Buckinghamshire, England) 
and all other products were reagent grade from Merck (Darmstadt, 
FRG) or Fluka. 
2.2. Purification of protein kinase C 
Protein kinase C was purified from rat brain by a modification of 
the procedure described by Wolf et al. 181. Purification was carried 
out by adsorption to and elution from inside-out erythrocyte vesicles 
followed by HPLC on a Mono Q 5/5 column. 
Inside out erythrocyte vesicles were prepared from human 
erythrocytes by hypotonic lysis in 10 mM Tris-HCI, pH 7.6 at 4°C 
followed by incubation in 0.1 mM EDTA for 45 min at 37°C. 
Five rat brains were homogenized in a Ca2+ buffer (20 mM Tris- 
HCl, pH 7.4 at 4”C, 20/g/ml leupeptin, 10 mM DTT, 1 mM 
CaClz). The enzyme was then released from the particulate fraction 
in EGTA-EDTA buffer (20 mM Tris-HCl, pH 7.6 at 4”C, 20 pg/ml 
leupeptin, 10 mM DTT, 5 mM EGTA, 2 mM EDTA) and this solu- 
ble enzyme preparation was incubated with inside-out erythrocyte 
vesicles (20 mg/ml protein) in the presence of 1 mM CaClz and 3 mM 
MgClz, in a Tris buffer (20 mM Tris-HCl, pH 7.6 at 25”C, 20 +g/ml 
leupeptin, 2 mM DTT and 1 mg/ml polyethylene glycol 20000). 
After incubation at room temperature for 15 mitt the vesicles with 
protein kinase C bound were resuspended in EGTA-EDTA buffer 
(20 mM Tris-HCl, 1 mM DTT, 2 mM EGTA, 1 mM EDTA) causing 
release of protein kinase C from the membranes. Following removal 
of the vesicles by centrifugation the supernatant, enriched in protein 
kinase C, was applied to a Mono Q 5/5 column equilibrated with a 
20 mM Tris-HCl buffer, pH 7.6 at 4°C containing 1 mM DlT, 
2 mM EGTA and 1 mM EDTA. Protein kinase C was eluted using 
a discontinuous NaCl gradient with peak activity eluted between 
160 mM and 170 mM NaCl. The protein was stable for several 
months when stored at -70°C in the presence of 1 mg/ml poly- 
ethylene glycol 20000 and 10% glycerol. 
Protein concentrations were determined by the method of Brad- 
ford [9] using bovine serum albumin as a standard. 
2.3. Assay of PKC activity 
Ca2+ and phospholipid dependent protein kinase activity was 
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determined using an assay mixture (total volume: 0.25 ml) containing 
20 mM Tris-HCI, pH 7.5 at 3O"C, 5 mM Mg-acetate, 0.2 mg/ml 
histone III-S, 1 mM CaCia, 0.04 mg/ml phosphatidylserine and 
10 FM [Y-~‘P)ATP (1~~ cpm/nmol). The reaction was started by 
the addition of 20 ~1 of enzyme fraction to the assay mixture and car- 
ried out at 30°C for 8 min. After termination of the reaction with 
0.35 ml of cold 12% trichloroacetic acid, 2% sodium pyrophosphate 
and 10 mg/ml bovine serum albumin, the precipitated protein was 
quantitatively transferred to filters (Millipore HA, 0.45 FM) which 
were then counted in 4 ml liquid scintillation cocktail. One unit of 
kinase activity is defined as the amount of enzyme catalyzing the in- 
corporation of 1 nmol 3zP into histone III-S per min. The enzyme 
preparation had a specific activity of 1000 nmol/min/mg. 
2.4. Cell culture 
Mouse neuroblastoma cells, clone NBZA, derived from the C-1300 
tumor cell line [lo] were kindly supplied by Dr U. Wiesmann 
(Kinderklinik, U~versit~t Bern). Cells were cultured in DMEM sup- 
plemented with 5% FCS and antibiotics (penicillin 60 U/ml and 
streptomycin 6O/rg/ml). The cells were maintained at 37°C in a 
humidified atmosphere of 5% CO2. 
Differentiation and growth curves: To study the effect of suramin 
on morphological changes, cells (5 x @/ml) were plated in Falcon 
6-well tissue culture plates and the drug (100rM) was added 24 h 
later. The medium or drugs were not changed during the course of 
the experiment. Viable cells were determined by the trypan blue dye 
exclusion method. 
To study the effect of suramin on growth, cells (2 x @/ml) were 
plated in Falcon 24-well tissue culture plates in DMEM containing 
0.2% FCS and allowed to recover for 24 h before treatment. Growth 
of cells was stimulated by changing the medium for that sup- 
plemented with 5% FCS, in the presence or absence of suramin at 
100 pM. Cells were removed from dishes every I2 h and counted in 
a haemocytometer. 
3. RESULTS AND DISCUSSION 
The inhibition of purified rat brain protein kinase C 
by suramin is shown in fig. 1. A half-inhibitory concen- 
tration of 30 FM, for the assay conditions employed, 
was calculated. The lack of inhibition, and sometimes 
the slight activation, of the enzyme at concentrations 
below 10 pM is, at present, not clear. A kinetic analysis 
of the inhibition of PKC by suramin is shown in fig.2. 
The type of inhibition appears to be competitive with 
respect o ATP (Ki = 10 PM). The data points were not 
fitted optimally by a straight line, suggesting the ex- 
70 . 
60 - 
50 _ 
40 - 
30 - 
20 - 
10 - 
ol....,‘.....‘.....‘...- ~~..~.-.~~.~~..I 
0 10 20 30 40 50 60 
Summin (pt.4) 
Fig. 1. Concentrationdependent inhibition of protein kinase C 
activity by suramin. Results are the mean of triplicate experiments. 
Assay conditions were as described in section 2. 
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Fig.2. Dixon plot of the inhibition of PKC by suramin. PKC activity 
was measured in the presence of different concentrations of suramin 
at two ATP concentrations, 10 /IM (of and 40 FM (A). Results are 
the mean of triplicate experiments. Assay conditions were as 
described in section 2. 
istence of heterogeneity in the preparation. Such a 
phenomenon may be consistent with a different degree 
of inhibition by suramin of the different isoforms of 
the enzyme. The lack of inhibition at low concentra- 
tions of suramin may be related to the same pheno- 
menon. The inhibition of the Na+,K’-ATPase [ 1 l] and 
Ca-ATPase [12] by suramin, together with the present 
results are consistent with previous kinetic and com- 
puter modelling studies of protein kinases from Trypa- 
nosomatida. In these studies suramin was shown to 
inhibit protein kinase I by competing for the ATP 
binding site [I] and computer modelling of phosphogly- 
cerate kinase have shown how suramin could be fitted 
to the ATP binding site and thereby inhibit kinase ac- 
tivity [13]. 
To investigate the effect of suramin on intact cells, 
quiescent cultures of neuroblastoma cells (clone NBZA) 
maintained in 0.1% FCS were stimulated to growth by 
the addition of 5% FCS to the culture medium. In un- 
treated cultures an increase of 20-fold in the cell 
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Fig.3. Effect of suramin on serum-induced proliferation of NBZA 
cells in culture. The quiescent cultures were stimulated by changing 
the medium to one containing 5% FCS, with (0) or without (A) 
suramin (1OOpM). At the indicated times, the number of tells was 
determined as described in section 2. 
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Fig.4. Effect of suramin on the morphology of NB2A neuroblastoma cells. Cells were plated at 1 x LOS/well in &well plates and suramin was 
added 24 h later in the presence of 2% FCS. After 48 h of treatment, the degree of differentiation, as evidenced by the enlargement of neurites, 
is observed in suramin-treated cells (B), but not in control cells (A). 
number was observed after 48 h incubation. The 
presence of 100 FM suramin in the culture medium pro- 
duced a diminution of approximately 50% in the rate 
of cell multiplication in the first 30 h. Subsequently, 
however, the rate of growth of the cells, in presence and 
absence of suramin, became equal (fig.3). The conclu- 
sion which can be drawn from this experiment is that 
suramin slows down, at least in the first 30 h of incuba- 
tion, the process of cell multiplication. Why the effect 
is not prolonged in time is not, at present, clear. What 
is, however, evident is that at 48 h of the treatment he 
cells have changed rather dramatic~ly their morpho- 
logy. The spherical and generally separated cells emit 
neurites, which in many cases are branched, indicating 
a certain degree of differentiation. The cells acquire a 
polygonal shape and tend to associate more frequently 
in lumps (fig.4). Whether suramin produces the above 
described morphologist changes by solely interacting 
with protein kinase C or by multiple interactions with 
different proteins (possibly utilizing ATP as a sub- 
strate) remains to be elucidated. The analogous 
findings obtained by staurosporine (manuscript in pre- 
paration), a potent PKC inhibitor, suggest a central 
role of PKC in the effects of suramin at a cellular level. 
The newly described inhibition of PKC through the in- 
teraction of suramin with the catalytic domain of the 
enzyme suggests that the inhibition of growth, and in- 
duction of differentiation in neuroblastoma cells, could 
be mediated through the inhibition of protein kinase C. 
However, other mechanisms by which this drug ex- 
hibits antitumor activity have been reported. Suramin 
was shown to block the binding of a range of tumor 
growth factors to their cell surface receptors thereby in- 
hibiting tumor growth [ 141, and another report suggests 
the antitumor effect may be due to the drug causing an 
increase in tissue glycosaminoglycans which have im- 
portant effects in tumor biology including differentia- 
tion [4]. However, since suramin is an inhibitor of 
protein kinase C we see this as an alternative reason for 
suramin antitumor activity. 
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